ストックスクリーナーアプリを入手
32.89
23.32%
-10.00
アフターアワーズ：
31.75
-1.14
-3.47%
Grail Inc (GRAL) 最新ニュース
Gravity study shows why the moon's two sides look so different - marketscreener.com
Health Care Sector Slips While Incannex Rockets Ahead - Finimize
Sector Update: Health Care - marketscreener.com
GRAIL and athenahealth partner to simplify ordering of cancer detection test - MSN
GRAIL outlines 2025 commercial growth plans and targets up to 30% US Galleri revenue increase - MSN
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Grail partners with athenahealth for MCED test ordering - Yahoo
Grail price target raised to $43 from $32 at Canaccord - TipRanks
GRAIL stock price target raised to $43 by Canaccord Genuity - Investing.com Canada
GRAIL Inc Reports Q1 2025 Earnings: Revenue Hits $31.8 Million A - GuruFocus
Earnings call transcript: Grail Inc Q1 2025 sees revenue growth, stock tumbles - Investing.com Nigeria
After-hours movers: American Eagle Outfitters, Aurora, GRAIL By Investing.com - Investing.com India
GRAIL Earnings Results: $GRAL Reports Quarterly Earnings - Nasdaq
GRAIL falls 16% after Q1 topline miss - MSN
GRAIL falls 16% after Q1 topline miss (GRAL:NASDAQ) - Seeking Alpha
Grail Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GRAIL Reports First Quarter 2025 Financial Results - TradingView
GRAIL shares tumble as Q1 loss persists despite revenue growth By Investing.com - Investing.com South Africa
GRAIL shares tumble as Q1 loss persists despite revenue growth - Investing.com Australia
Grail reports Q1 EPS ($3.10), consensus ($3.80) - TipRanks
Earnings Flash (GRAL) GRAIL INC. Posts Q1 Revenue $31.8M, vs. FactSet Est of $35.2M - marketscreener.com
GRAIL And Athenahealth Partner To Streamline Galleri Multi-Cancer Test Ordering - Nasdaq
GRAIL, athenahealth partner for cancer test (GRAL:NASDAQ) - Seeking Alpha
GRAIL partners with athenahealth for cancer test orders By Investing.com - Investing.com India
Wells Fargo & Company MN Takes $90,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
GRAIL partners with athenahealth for cancer test orders - Investing.com Australia
Grail And Athenahealth Team Up To Offer Healthcare Providers Streamlined Ordering Of Grail's Galleri® Multi-Cancer Early Detection (Mced) Test - marketscreener.com
GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test - PR Newswire
Stifel Financial Corp Makes New Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Raymond James Financial Inc. Takes $476,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
SEC ends probe of Illumina’s Grail acquisition - MedTech Dive
Illumina confirms SEC has closed investigation into $8B Grail deal - Endpoints News
Mariner LLC Makes New $190,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
Envestnet Asset Management Inc. Buys New Shares in Grail, Inc. (NASDAQ:GRAL) - Defense World
Grail’s CFO Aaron Freidin sells $1.4 million in stock By Investing.com - Investing.com Nigeria
Grail’s CFO Aaron Freidin sells $1.4 million in stock - Investing.com Australia
Lobbying Update: $500,000 of GRAIL INC. (FORMERLY GRAIL LLC) lobbying was just disclosed - Nasdaq
JPMorgan Chase & Co. Sells 48,591 Shares of Grail, Inc. (NASDAQ:GRAL) - Defense World
Why GRAIL, Inc. (GRAL) is Surging in 2025 - Insider Monkey
GRAIL to Announce First Quarter 2025 Financial Results - The Victoria Advocate
LPL Financial LLC Invests $244,000 in Grail, Inc. (NASDAQ:GRAL) - Defense World
GRAIL to Reveal Latest Cancer Detection Financial Performance: Q1 2025 Results Coming May 13 - Stock Titan
CEO Sam Hazen on where technology will be HCA's 'holy grail' - The Business Journals
GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting - PR Newswire
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence - Benzinga
Opinion | The FTC vs. the War on Cancer - WSJ
This Cancer Test Could Become Routine—and a Big Seller, Says Analyst - Barron's
Canaccord starts Grail with a Buy, sees ‘solid upside’ - TipRanks
Canaccord sets $32 target on GRAIL stock with buy rating By Investing.com - Investing.com Nigeria
Canaccord Genuity Initiates GRAIL at Buy With $32 Price Target - marketscreener.com
Canaccord sets $32 target on GRAIL stock with buy rating - Investing.com
GRAIL, Inc. (GRAL): A Bull Case Theory - MSN
1.15%
大文字化:
|
ボリューム (24 時間):